Mono-menotropins Versus rFSH Protocol on Embryo Quality
NCT ID: NCT02418533
Last Updated: 2020-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
109 participants
INTERVENTIONAL
2015-03-31
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This pilot study is expected to significantly contribute to optimization of treatment regimens and stimulation protocols to optimize embryo quality.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of IVF-M HP Inj. vs. Menopur® Inj.
NCT02458768
Ovarian Stimulation With Recombinant Gonadotropins vs. Human Menopausal Gonadotropin in In Vitro Fertilization
NCT02322398
MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population
NCT02554279
Efficacy and Safety of Medication Used to Stimulate Ovulation
NCT02715336
Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)
NCT00805935
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
One-hundred women between the ages of 21 to 38 (inclusive) pursuing IVF treatment for infertility and preimplantation genetic screening (PGS).
Pre-medication All study patients will take oral contraception pills (OCP) starting between day 2-4 of the menstrual cycle before controlled ovarian stimulation (COS) is started for IVF, and they are continued for 21 days. Cycle preparation using an oral contraceptive pill is thought to be important in improving follicular homogeneity.
Randomization Randomization of patients into the Stimulation Group 1 (Mono-Menotropin Protocol) or Stimulation Group 2 (rFSH) will occur at OCP start using a computerized randomization program.
Ovarian Stimulation Stimulation Group 1: Mono-Menotropin Protocol Fifty patients will undergo the standard of care COS for IVF using Menopur (Ferring, Parsippany, New Jersey (NJ) USA) only. Patients will receive 300 IU of Menopur injected subcutaneously daily for the first five days of stimulation. Thereafter, Menopur may be adjusted (to optimize ovarian response by patient's physician) in 75 IU increments up to a total of 450 IU Menopur daily up to and including day of hCG trigger.
Stimulation Group 2: rFSH Protocol Fifty patients will undergo the standard of care controlled ovarian stimulation (COS) for IVF using Gonal-f (EMD Serono, USA) protocol. Patients will receive 300 IU of Gonal-f administered subcutaneously daily for the first five days of stimulation. Thereafter, Gonal-f may be adjusted (to optimize ovarian response by the patient's physician) in 75 IU increments up to a total of 450 IU daily up to and including day of hCG trigger.
Menopur and Gonal-f are widely used in controlled ovarian stimulation cycles for the development of multiple follicles in assisted reproductive technology (ART) programs.
Luteinizing Hormone (LH)-surge Suppression Gonadotropin Releasing Hormone (GnRH) antagonist will be used to suppress endogenous pituitary LH for the prevention of premature LH surges. Patients will receive 0.25 mg/day of Ganirelix Acetate or Cetroelix Acetate when follicle size reaches 12 mm and will continue up to and including day of hCG trigger.
HCG Trigger Human chorionic gonadotropin (hCG) will be used intramuscularly (IM) in both stimulation groups to induce oocyte maturation 36 hours prior to the oocyte retrieval procedure
Cycle Monitoring Cycles will be monitored with follicular ultrasound measurements and serum estradiol concentrations throughout ovarian stimulation. HCG will be given IM when at least three follicles reach a diameter of ≥17 mm. Egg retrieval will be conducted by transvaginal ultrasound 36 h after hCG administration.
Insemination All mature oocytes will have intracytoplasmic sperm injection (ICSI) or standard insemination to achieve fertilization.
Embryo Development Two-pronuclei (2pn) embryos will be placed in the Eeva dish after fertilization check at 16-18 hours post ICSI. To maintain a continuous and uninterrupted imaging process from day 1 through day 3, no media changes or dish removal from the incubator will be permitted. On day 3, imaging will be stopped just before routine embryo grading will be performed according to Society for Assisted Reproductive Technology (SART) standards. Cell number and quality score based on symmetry of cells and percent fragmentation will be recorded. Embryos will be tracked individually. Software will automatically measures cell division timings and provide quantitative information regarding embryo development. Embryo grading day 5 will be performed according to standard operating procedure. Blastocysts will be biopsied on day 5 or 6. Biopsies will be sent to a genetics laboratory (Reprogenetics, New Jersey) for aCGH euploidy testing. Biopsied blastocysts will be vitrified for future frozen embryo transfer (FET) cycle/s, in which euploid blastocyst/s with the correct number of chromosomes will be thawed and transferred back to the uterus in an attempt to achieve pregnancy.
Abnormal embryos (aneuploidy embryos with the incorrect number of chromosomes) may be donated to research or discarded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mono-menotropin protocol
Stimulation Group 1: Mono-Menotropin Protocol Fifty patients will undergo the standard of care COS for IVF using Menopur only. Patients will receive 300 IU of Menopur injected subcutaneously daily for the first five days of stimulation. Thereafter, Menopur may be adjusted (to optimize ovarian response by patient's physician) in 75 IU increments up to a total of 450 IU Menopur daily up to and including day of hCG trigger.
menotropin
Menopur is used for controlled ovarian stimulation (COH)
rFSH protocol
Stimulation Group 2: Recombinant follicle stimulating hormone (rFSH) Protocol Fifty patients will undergo the standard of care COS for IVF using Gonal-f (EMD Serono, USA) Protocol. Patients will receive Gonal-f (300 IU) administered subcutaneously daily for the first five days of stimulation. Thereafter, Gonal-f may be adjusted (to optimize ovarian response by the patient's physician) in 75 IU increments up to a total of 450 IU daily up to and including day of hCG trigger.
Recominant Follicle Stimulating Hormone (rFSH)
Gonal-f is used for controlled ovarian stimulation (COH)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
menotropin
Menopur is used for controlled ovarian stimulation (COH)
Recominant Follicle Stimulating Hormone (rFSH)
Gonal-f is used for controlled ovarian stimulation (COH)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Day 2-4 Follicle Stimulating Hormone (FSH) \< 10 IU/ml, LH\< 12 IU/ml, and estradiol \<50 pg/ml on day 2-4 of menstrual cycle
* Antimullerian Hormone \> 1.5
* Between 10 and 20 basal antral follicles on day 2-4 of the menstrual cycle
* Body weight \>50 kg, with BMI \> 18 and \< 32 kg/m2
Exclusion Criteria
* Polycystic ovarian disease
* Endometriosis greater than Stage I
* Testicular aspirated sperm
* Preimplantation Genetic Diagnosis (PGD) for single gene disorder
* Preimplantation Genetic Screening (PGS) banking cycles
* Donor Egg Cycles
21 Years
38 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Main Line Fertility Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael J Glassner, MD
Role: PRINCIPAL_INVESTIGATOR
Main Line Fertility
Sharon H Anderson, PhD
Role: STUDY_DIRECTOR
Main Line Fertility
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Main Line Fertility Center
Bryn Mawr, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Main Line Fertility website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MLFC-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.